Who makes [13C415N3] LY3314814?

[13C415N3] LY3314814 is developed by AstraZeneca.

What development phase is [13C415N3] LY3314814 in?

[13C415N3] LY3314814 is in Phase 1.

Last reviewed 2026-04-19 · How we verify

[13C415N3] LY3314814

AstraZeneca · Phase 1 active Small molecule

At a glance

Generic name	[13C415N3] LY3314814
Sponsor	AstraZeneca
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[13C415N3] LY3314814 CI brief — competitive landscape report
[13C415N3] LY3314814 updates RSS · CI watch RSS
AstraZeneca portfolio CI